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Introduction
Medical advances in the breast cancer ﬁ  eld  have 
dramatically altered the overall 5-year survival rate for 
women in the United States from 63% in the 1960s to 
90% as of 2010 [1]. Despite these advances, the 5-year 
survival rate is a mere 23% for women diagnosed with 
distant meta  static disease [1]. Accordingly, basic 
researchers and clini  cians have been working to combat 
breast cancer mortality by unraveling the molecular 
mechanisms that underlie metastasis, in an eﬀ  ort  to 
improve treatment regimens and ultimately prognostic 
outcomes.
A recent focus in breast cancer metastasis research is 
the epithelial-to-mesenchymal transition (EMT). Classical 
EMT is a critical developmental program that entails the 
transdiﬀ   erentiation of epithelial cells to mesenchymal 
cells, giving rise to diﬀ   erent cell types, often in new 
locales [2]. As tumors progress, a subset of epithelial 
cancer cells may attain attributes of mesenchymal cells, a 
process that is broadly referred to as an oncogenic EMT. 
Amongst other things, an oncogenic EMT can result in 
increased migratory and invasive capabilities that may in 
turn contribute to metastatic dissemination. Oncogenic 
EMTs are not equivalent to developmental EMTs, as 
mesenchyme, by deﬁ   nition, is embryonic in origin. 
Instead, oncogenic EMTs should be viewed more as a 
partial EMT, in which carcinoma cells gain characteristics 
of mesenchymal cells, but may not fully lose epithelial 
characteristics (see ‘Type III epithelial-to-mesenchymal 
transition’ section for further discussion). Th  is inter-
mediate phenotype represents a plastic state, and it is 
speculated that plastic cells that have undergone an EMT 
to escape from a primary tumor must subsequently 
undergo the reverse mesenchymal-to-epithelial transition 
(MET) prior to colonizing a secondary site [3]. Such 
plasticity may also allow for cellular alterations that 
facilitate newly uncovered and important functional 
characteristics that have been linked to EMT, such as 
increased tumor-initiation and self-renewal capacity [4,5] 
and increased resistance to conventional therapies [6,7]. 
Th   us, the role of epithelial plasticity will be an underlying 
theme throughout this review.
While the debate regarding the exact role of EMT in 
human breast cancers continues [8], such debate should 
not distract from the fact that the study of oncogenic 
EMT has led to signiﬁ  cant ﬁ  ndings that have widespread 
implications in the treatment of breast cancer patients. 
Th   is review highlights such important ﬁ  ndings.
Abstract
The epithelial-to-mesenchymal transition (EMT) is a 
critical developmental process that has recently come 
to the forefront of cancer biology. In breast carcinomas, 
acquisition of a mesenchymal-like phenotype 
that is reminiscent of an EMT, termed oncogenic 
EMT, is associated with pro-metastatic properties, 
including increased motility, invasion, anoikis 
resistance, immunosuppression and cancer stem cell 
characteristics. This oncogenic EMT is a consequence 
of cellular plasticity, which allows for interconversion 
between epithelial and mesenchymal-like states, and is 
thought to enable tumor cells not only to escape from 
the primary tumor, but also to colonize a secondary 
site. Indeed, the plasticity of cancer cells may explain 
the range of pro-metastatic traits conferred by 
oncogenic EMT, such as the recently described link 
between EMT and cancer stem cells and/or therapeutic 
resistance. Continued research into this relationship will 
be critical in developing drugs that block mechanisms 
of breast cancer progression, ultimately improving 
patient outcomes.
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EMT occurs in a number of contexts with characteristic 
diﬀ  erences, and while three diﬀ  erent subtypes have been 
classiﬁ  ed (types I, II and III), there are large areas of 
overlap [9,10]. In general, EMT programming allows 
epithelial cells to become invasive and motile mesen-
chymal or mesenchymal-like cells that are no longer 
spatially restricted by extracellular matrix [9]. Th  is 
programming occurs in part through loss of apical-basal 
polarity and tight cell-cell contacts, with a concomitant 
gain in front-back end polarity and focal cell-cell 
contacts. In addition, the process of EMT leads to the 
formation of ﬁ  lopodia, accompanied by a switch from 
integrin receptors that mediate cell-cell adhesion to cell-
extracellular matrix adhesion-speciﬁ  c integrins that are 
critical for cell motility [11,12]. Th   e epithelial cytokeratin-
based intermediate ﬁ   lament network is replaced with 
vimentin (VIM) along with actin (ACTA1) stress ﬁ  ber 
formation, yielding a more spindle-like shape in vitro 
[11]. An increase in the mesenchymal N-cadherin (CDH2) 
also facilitates focal cell-cell contacts and mobility, while 
the epithelial E-cadherin (CDH1) functionally dissipates 
through either down-regulation or relocalization away 
from the adherens junctions in the membrane [13].
Type I and II epithelial-to-mesenchymal transition
Type I EMT occurs during development and is respon-
sible for the complex tissue types and organization 
present in metazoans [9]. A classic example of this EMT 
in humans is the formation of the primitive streak that 
deﬁ   nes the ﬁ   rst embryonic axis and designates where 
cells will ingress to form new tissue layers during 
gastrulation [2]. In some instances of type I EMT, mesen-
chymal cells revert back to an epithelial phenotype in a 
MET, such as during nephrogenesis, when the meta-
nephric mesenchyme transitions into epithelial nephric 
tubules, re-establishing epithelial structures at novel sites 
[11]. Th  us, although some type I EMTs are permanent, 
interconversion between epithelial and mesenchymal 
pheno  types (that is, epithelial plasticity) is observed 
during development.
Type II EMTs are those that occur in wound healing 
and ﬁ  brosis [9,10]. In some instances, ﬁ  brosis can arise as 
a result of inappropriate presence of myoﬁ  broblasts at an 
injured/inﬂ   amed site due to an EMT response to 
persistent injury or inﬂ   ammation [9]. During wound 
healing, an EMT causes integrin changes and lamelli-
podia formation that allow keratinocytes at injured edges 
to migrate to close a wound [14]. An important aspect of 
the wound healing response is that only cells of the 
leading edge appear to undergo an EMT [14]. As the 
leading cells migrate, they pull a sheet of keratinocytes 
behind them. Th   e cell-cell contacts required during this 
co-migration indicate that these cells only undergo a 
partial EMT, in that an individual cell exhibits spatially 
restricted epithelial and mesenchymal-like properties 
simultaneously, demonstrating another instance of 
epithelial plasticity. Type I and II EMTs are more 
thoroughly reviewed elsewhere [9,14,15].
Type III epithelial-to-mesenchymal transition
Type III EMT, or oncogenic EMT, is the name given to an 
EMT-like process that is observed in carcinoma cells, and 
is associated with tumor progression and metastasis 
[9,10]. EMT-associated gains in migration and invasion 
are thought to allow tumor cells to better navigate 
elements of the metastatic cascade, such as invasion 
through the basement membrane and intravasation into 
the circulatory system. Additionally, oncogenic EMT is 
linked to other pro-metastatic phenotypes, including 
resistance to chemo- and radiation therapy, self-renewal, 
evasion of the immune system and anoikis resistance 
(Figure 1). It should be noted that the scope or complete-
ness of a type III EMT is often less than that of a type I 
EMT; depending on the cellular and microenvironmental 
context, diﬀ  erent EMT-associated traits may or may not 
be acquired. Th  us, oncogenic EMT could be deﬁ  ned as 
an EMT-like process in which carcinoma cells gain 
mesenchymal-like characteristics and/or lose epithelial 
characteristics; morphological alterations may or may 
not accompany such changes (see ‘Breast cancer EMT 
mediators’ section for further discussion).
If carcinoma cells that have undergone an oncogenic 
EMT retain some epithelial features, while gaining mesen-
chymal characteristics, does that mean that a complete 
conversion never occurs? Unfortunately, complete loss of 
epithelial characteristics from a carcinoma cell would be 
diﬃ   cult to detect in human cancers, as these cells would 
no longer morphologically or molecularly appear 
epithelial and may be confused with stromal cells. None-
theless, evidence for an oncogenic EMT does exist in 
mouse models and in human tumors [16-18]. A recent 
study used fate mapping to examine MYC-initiated 
breast tumors in mice, speciﬁ   cally focusing on histo-
logically identiﬁ   ed tumor-adjacent stroma and breast 
tumor epithelium. Using a Cre and Rosa26LoxP system to 
mark tumor cells, an epithelial promoter-driven Cre 
marked tumor-adjacent stroma, which also stained 
positive for epithelial cytokeratins, indicative of late type 
III EMT where carcinoma cells have transitioned into 
mesenchymal-like cells [19]. Conversely, tumor epithelia 
were marked with a ﬁ  broblast  promoter-driven  Cre, 
suggestive of early stage type III EMT where carcinoma 
cells are beginning to acquire mesenchymal charac  ter-
istics [19]. Additional studies further demonstrate the 
presence of an oncogenic EMT, where a gain of mesen-
chymal characteristics occurs while epithelial charac-
teristics are in part maintained. For example, Sine oculis 
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Page 2 of 13homeobox homolog 1 (SIX1) overexpression in mammary 
epithelial cells of transgenic mice leads to tumors, 21% of 
which are sarcomatoid in morphology and are negative 
for CDH1 and positive for α-Smooth muscle actin 
(ACTA2) [20]. Importantly, these tumors are also 
cytokeratin18 (KRT18) positive, supporting an epithelial 
origin [20]. Of the non-sarcomatoid SIX1 tumors, almost 
80% appeared morphologically epithelial, but contained 
regions in which membranous CDH1 is decreased and 
nuclear β-catenin (CTNNB1) is upregulated, indicative of 
a cell in the earlier stages of EMT [20]. Indeed, there are 
now several additional studies demonstrating such an 
oncogenic EMT within mouse and human breast cancer 
cell lines and tumors [16-18].
Breast cancer EMT mediators
Many groups have dedicated signiﬁ  cant eﬀ  ort towards 
elucidating causes and eﬀ  ects of EMT in breast cancer, 
yielding a better, though still incomplete, understanding 
of the process. Numerous mediators of EMT have been 
discovered, including transcription factors, signaling 
molecules and microRNAs (miRNAs). Many downstream 
markers are used to distinguish between epithelial and 
mesenchymal-like phenotypes, including loss of epithelial 
proteins that exist in junctional complexes. A variety of 
proteins that are down-regulated in response to an EMT 
include CDH1, plakoglobin (JUP), occludin (OCLN), 
zonula occludens1 (TJP1), α-catenin (CTNNA3) and 
claudins 3/4/7 (CLDN-3/4/7) [10]. On the other end of 
the spectrum, the promotion of a mesenchymal-like 
phenotype is indicated by the up-regulation of proteins 
such as ﬁ   bronectin (FN1), CDH2, VIM, ACTA2 and 
nuclear CTNNB1 [10]. As noted above, carcinoma cells 
may not completely lose their epithelial phenotype 
during an oncogenic EMT and may express epithelial and 
mesenchymal markers simultaneously [3].
A common theme among oncogenic EMT inducers is 
their crucial role in type I EMT. It has become 
increasingly evident that improper activation of develop-
mental EMT inducers in adults gives rise to an out of 
context EMT-like program that contributes to the 
progression of breast cancer, as well as other cancers. A 
few examples of transcription factors and signaling 
pathways known to play a role in both type I and type III 
EMT include Twist1 (TWIST1), SIX1, Snail1 (SNAI1) 
and Ladybird homeobox (LBX1) and the Wnt and trans-
forming growth factor-β (TGF-β) signaling pathways [2]. 
Th  e relationship between developmental regulators and 
type III EMT is more thoroughly reviewed in other 
bodies of work [2,15,21].
Transcription factors
Th   e dissolution of adherens junctions is a critical step of 
EMT, with loss/decrease or relocalization of CDH1 as the 
most commonly used determinant of the EMT pheno-
type. Not surprisingly, a number of EMT inducers are 
Figure 1. Functional consequences of a type III epithelial-to-mesenchymal transition. An oncogenic epithelial-to-mesenchymal transition 
(EMT) in a breast carcinoma cell gives rise to a tumor cell with mesenchymal-like features. This transition can lead to the acquisition of a number of 
pro-metastatic features, including increased motility, invasiveness, anoikis resistance and evasion of the immune system. Recently, the acquisition 
of cancer stem cell-like properties has been added to this list (that is, self-renewal, multipotency, therapeutic resistance), resulting in signifi  cant 
cross-talk between the EMT and cancer stem cell fi  elds.
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ﬁ  nger proteins SNAI1 [22,23], Snail2 (SNAI2) [24], Zeb1 
(ZEB1) [25] and Zeb2 (ZEB2) [26] each directly repress 
transcription of CDH1 in mammary cells by binding the 
E-boxes (CANNTG) located in the CDH1 proximal 
promoter, as do the basic helix-loop-helix factors E12/
E47 (TCF3) [27] and TWIST1 [28]. A number of other 
transcription factors cause relocalization of junctional 
CDH1, including SIX1 [29], Goosecoid (GSC) [30] and 
Forkhead box C2 (FOXC2) [31]. Interestingly, knock-
down of CDH1 alone is suﬃ   cient to induce an EMT [32], 
highlighting the signiﬁ  cance of repressors of CDH1 in 
the induction of an EMT.
Much research has focused on direct repressors of 
CDH1, and in addition to laboratory based studies, 
clinical associations with breast cancer have been 
demon  strated for many of these repressors. Analysis of 
breast cancer patients has associated SNAI1 with tumor 
recurrence, while SNAI2 is associated with tumor recur-
rence and metastasis [33,34]. High levels of ZEB1/2 have 
similarly been found to correlate with poor survival, 
outcome and grade in numerous cancers, including 
breast [35,36]. Surprisingly, however, a recent study by 
Montserrat and colleagues demonstrates that lower 
ZEB1 transcript levels correlate with worse overall sur-
vival and disease-free survival in breast cancer patients 
[37]. TWIST1 analyses are also inconsistent between 
studies: nuclear TWIST1 staining in the epithelial 
compartment of breast carcinomas is associated with 
poor survival [35], while TWIST1-negative breast tumors 
have also been associated with worse overall survival 
[37]. Unfortunately, because these studies employ diﬀ  er-
ent cohorts of women, who may be at diﬀ  erent stages of 
the disease and have been subjected to diﬀ  erent thera-
peutic regimens, it is diﬃ   cult to draw ﬁ  rm conclusions 
from these opposing data. Well-controlled studies are 
needed, including microdissection of the leading edge of 
tumors where oncogenic EMT is thought to occur, to 
truly determine the prognostic value of EMT inducers.
Indirect repression of CDH1 is also accomplished by 
EMT inducers, including SIX1, GSC and FOXC2 [29-31]. 
SIX1 drives an oncogenic EMT that is dependent on its 
ability to activate TGF-β signaling and relocalize CDH1 
away from the membrane in MCF7 breast cancer cells 
[29]. GSC can induce a type III EMT likely through 
activation of SNAI1/2 and TWIST1 [30], while FOXC2 
has been shown to relocalize CDH1 away from adherens 
junctions [31]. Recently, p53 (TP53), Twist2 (TWIST2) 
and Forkhead box Q1 (FOXQ1) have been added to this 
list of onco  genic EMT inducers. Both TWIST2 and 
FOXQ1 decrease activity of the CDH1 promoter, but it is 
not clear if this interaction is direct [18,38,39]. Th  e 
mechanism of action for TP53 is indirect control over 
ZEB1/2 protein levels, through direct regulation of the 
miR-200 and miR-192 families in breast [40] and 
hepatocellular cancer models [41].
One puzzling aspect of CDH1 expression in breast 
cancer patients occurs in those diagnosed with lobular 
cancers, which are largely (55 to 85%) CDH1 negative 
[42]. Th  ese tumors do not appear morphologically 
mesen  chymal-like [8], though detection of VIM occurs 
on occasion [43]. Interestingly, it has been demonstrated 
that inactivating CDH1 mutations occur in 56% of all 
lobular tumors [42], and breast cancer cell lines with 
CDH1 truncating mutations have a distinct epithelial 
expression proﬁ  le when compared to cell lines where the 
CDH1 promoter is silenced, which exhibit a ﬁ  broblastic 
proﬁ   le [44]. Th  is suggests CDH1 down-regulation by 
mutation is largely not associated with EMT. Clearly, our 
understanding of the role of CDH1 in lobular cancers is 
still incomplete and requires further analysis.
Major signaling pathways
In addition to transcription factors, several signaling 
pathways are known to induce an EMT, such as the TGF-
β [45], epithelial growth factor (EGF) [46], Wnt [47], 
Notch [48] and Hedgehog pathways [49]. Not surpris-
ingly, these pathways often activate the aforementioned 
transcription factors. Examples include TGF-β and EGF 
signaling, which both lead to activation of SNAI1/2, 
TWIST1 and ZEB1/2, while TGF-β also up-regulates 
FOXC2 [45,46,50]. In addition, Notch, Hedgehog and 
Wnt signaling mediate an EMT through activation of 
SNAI1/2 [47-49]. Some of these transcription factors can 
in turn activate signaling pathways to promote an EMT 
[50], such as SIX1, which activates both TGF-β and Wnt 
signaling [20,29], demonstrating signiﬁ  cant  cross-talk 
between EMT regulators.
EMT signaling pathways can also be enhanced via 
activation of a ligand released from the tumor micro-
environment. For example, matrix metalloproteases and 
a disintegrin and metalloproteases (ADAMs) can be up-
regulated as a result of transformation [21,51]. Up-
regulation of MMPs and ADAMs can then lead to an 
increase in processing of pro-ligands such as TGF-β1 
(TGFB1) and TNF-α [52,53], ultimately enhancing EMT. 
Because signaling pathways in EMT have been exten-
sively reviewed, we refer readers to the following reviews 
for more detailed descriptions of this topic [45,46,49].
MicroRNAs
Relatively recently, a class of small non-coding RNAs, 
termed miRNAs, was discovered. Th  ese post-transcrip-
tional inhibitors target mRNAs through sequence speci-
ﬁ  city, directing cleavage of the mRNA or translational 
inhibition [54]. As miRNAs play a role in development 
[55], it is not surprising that they have also been 
implicated in the induction of EMT. Th   e most frequently 
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miR-200 family, which consists of miR-200a/b/c, miR-141 
and miR-429. Repression of these miRNAs leads to an 
EMT, at least in part by relieving down-regulation of 
ZEB1/2 [56,57]. Interestingly, ZEB1/2 can directly repress 
transcription of miR-200 family members, complet  ing a 
double-negative feedback loop [57,58]. While miR-200c 
maintains the epithelial phenotype by keeping CDH1 
levels high, it also represses FN1 [59], thus repressing the 
mesenchymal phenotype. On the other hand, miR-9 and 
miR-495 repress the epithelial arm of EMT by directly 
targeting CDH1 for degradation, thus promoting a more 
mesenchymal-like state [60,61].
EMT-associated signaling pathways can also be 
inﬂ  uenced by miRNAs. Suppression of miR-448 gives rise 
to an EMT, both in vitro and in vivo, through indirect up-
regulation of amphiregulin (AREG), resulting in increased 
EGF signaling [62]. In the TGF-β pathway, the downstream 
co-activator SMAD family member 4 (SMAD4) up-
regulates miR-155, which is required for EMT in a non-
tumorigenic mammary model in vitro [63]. In contrast, 
miR-155 prevents EMT in vivo in a breast cancer model 
[64]. As TGF-β signaling is known to switch from tumor-
suppressive to tumor-promotional during cancer progres-
sion [45], perhaps the diﬀ  erence in the transformed state 
of the cells is responsible for the opposite eﬀ  ects observed 
with miR-155 expression. A similar up-regulation of miR-
29a leads to an EMT in murine mammary cells, but only in 
conjunction with RAS expression [65]. Th  us, it appears 
transformation itself may play a role in mediating the 
eﬀ  ects of miR-155 and miR-29a on EMT, emphasizing the 
importance of cellular context.
Epithelial-to-mesenchymal transition networks
Th   e complex process of EMT is historically thought to be 
controlled by master regulators [11]. While some of the 
above examples appear deserving of this label, there is a 
level of complexity in the EMT process that is not fully 
understood and suggests that multiple molecules act 
together to mediate EMT, rather than master regulators 
acting on their own. For example, SNAI2 is necessary for 
TWIST1-mediated down-regulation of CDH1 and up-
regulation of various mesenchymal genes [66], while 
cooperation between SNAI1 and TWIST1 is needed to 
achieve maximal up-regulation of ZEB1 [67]. Interest-
ingly, however, ZEB1 levels can eventually increase 
without the SNAI1-TWIST1 partnership [67]. Investi  ga-
tions into this ‘EMT interactome’ have revealed that 
many individual EMT inducers are able to up-regulate 
other EMT activators, though they are not necessarily 
dependent on this cross-talk to maintain activity [50,68]. 
As multiple feedback loops exist between EMT 
mediators, these intricate relationships are just beginning 
to be understood.
Impact of EMT on breast cancer: metastasis, cancer 
stem cells and therapeutics
EMT and metastasis
Since oncogenic EMT is observed in many breast cancer 
models, what then, is the relevance of this process to the 
human disease? It has been argued that EMT is critical 
for metastasis and, indeed, many EMT regulators are 
capable of inducing metastasis. Examples include 
TWIST1 [69], FOXC2 [31], FOXQ1 [38,39] and SIX1 
[29], all of which generate an oncogenic EMT in breast 
cancer models, induce metastasis to distant organs in 
these same models and are associated with poor 
outcomes in breast cancer. Importantly though, patient 
metastases typically reﬂ   ect the primary carcinoma 
histologically, implying that if a carcinoma cell that 
underwent an oncogenic EMT escaped the primary 
tumor and was responsible for the colonization of a 
distant site, a MET must have occurred at some point.
But, has an MET ever been observed in breast cancer 
models? Indeed, multiple recent studies suggest that 
MET can occur in breast cancer models. For example, Chao 
and colleagues [70] demonstrated, using the mesenchymal-
like, CDH1-negative MDA-MB-231 breast cancer line and 
primary human explants, that co-culture with hepato  cytes 
could restore a more epithelial morphology to MDA-
MB-231 cells, in part by decreasing CDH1 promoter 
methylation, resulting in increased levels of CDH1. As 
micrometastases from MDA-MB-231-initiated primary 
tumors were found to contain membranous human 
CDH1  in vivo [70], the possibility of MET or mesen-
chymal-to-epithelial reverting transition is certainly 
feasible within cancer [70]. In addition, a study by Asiedu 
and colleagues [16] used a NEU-driven mouse breast 
cancer model to induce an EMT with TGFB1 and TNF in 
vitro, which up-regulated CDH2 and silenced CDH1. 
After these mesenchymal-like cells were subcuta  neously 
injected into mice to form tumors, CDH1 became re-
expressed, but this reversion disappeared after in vitro 
culture of the cells retrieved from the tumor [16]. Th  ese 
data suggest that MET does occur, and that it is highly 
dependent on signals from the host microenvironment.
It is inherent to a metastasis model in which an onco-
genic EMT is followed by a MET that a high degree of 
plasticity must be exhibited by the cancer cells. 
Interestingly, when Dykxhoorn and colleagues examined 
an isogenic mouse breast cancer cell line series (4T1 
series) with varying metastatic potential [71], they found 
that the highly metastatic 4T1 line displays predomi-
nantly epithelial characteristics, though it also expresses 
the mesenchymal marker VIM [72]. While this seems 
counter to the argument in support of the role of EMT in 
metastasis, one interpretation of the data is that the 4T1 
cell line exists in a highly plastic state, retaining epithelial 
characteristics while also expressing mesenchymal ones, 
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tial. Th  e plasticity may indicate that given the right 
contextual signals, this cell line is primed to interchange 
between states, such as an in vivo oncogenic EMT and 
MET, thereby aﬀ  ecting early and late stage metastasis, 
respectively. In an additional cell line in the 4T1 series, 
exogenous expression of the miR-141-200c cluster in the 
non-metastatic, mesenchymal-like 4TO7 cell line induced 
a MET as expected, but also increased tumor-initiation 
and metastases [72]. To better understand these ﬁ  ndings, 
Korpal and colleagues [73] compared orthotopic against 
intravenous injections, in the same system, and found 
that the miR-200 family prevented 4TO7 invasion and 
intravasation during early state metastasis, while promot-
ing eﬃ   cient colonization of a secondary site in late stage 
metastasis. Akin to the 4T1 line, the 4TO7 line may 
already be primed for EMT, with the miR-200 family 
enabling 4TO7 cells to undergo the MET portion of the 
EMT-MET axis to establish metastases. Whether 4T1 
and/or 4T07 cells actually interconvert between epithelial 
and mesenchymal-like states in vivo remains to be deter-
mined, and will be important in understanding the 
generality of EMT as a mediator of the metastatic 
process.
Recent work by Tsuji and colleagues [74] provides an 
explanation other than interconversion between onco-
genic EMT and MET for how an oncogenic EMT may 
contribute to metastasis: cooperativity between epithelial 
and more mesenchymal-like cancer cells. In this study, 
p12 (CDK2AP1) induction of EMT in hamster HCPC-1 
cheek carcinoma cells led to increased in vivo invasion 
and survival in the circulatory system; however, these 
cells were not able to colonize the lung. Alternatively, 
epithelial HCPC-1 cells formed lung metastases when 
injected intravenously, yet could not invade or access the 
vasculature when injected subcutaneously [74]. Subcuta-
neous injection of a mixture of diﬀ  erentially  tagged 
mesenchymal-like and epithelial HPCP-1 cells allowed 
both cell types to be found in the circulation, with the 
epithelial HPCP-1 cells forming lung metastases [74]. 
Th  is led the authors to postulate that, at least in the 
HPCP-1 model, EMT is necessary but not suﬃ   cient for 
metastatic colonization [74] (Figure 2a). Such results are 
not observed in all studies, however. For example, MCF7 
breast cancer cells that undergo a SIX1-induced EMT 
form more distant metastases than control cells, in both 
orthotopic and intracardiac injection models, without 
co-inclusion of the parental epithelial MCF7 cell line [29] 
(Figure  2b). Th  ese studies can be reconciled if SIX1 
imparts a more plastic phenotype on epithelial cells 
compared to CDK2AP1, allowing the SIX1-expressing 
MCF7 cells to convert back to an epithelial state at the 
secondary site. Alternatively, it is possible that MCF7 
cells are more amenable to interconverting than HPCP-1 
cells, thus not requiring the cooperation of mesenchymal-
like and epithelial cells.
In addition to EMT contributing to metastasis via 
increased cellular migration and invasion, an oncogenic 
EMT is known to impart anoikis resistance, which would 
be expected to aid the survival of tumor cells in the 
vasculature [3]. A SNAI1-induced EMT also increases 
immunosuppression, providing yet another mechanism 
by which EMT may promote metastatic dissemination 
[2]. Taken together, the majority of oncogenic EMT-
derived gains in function appear to be pro-metastatic 
(Figure 1).
EMT and cancer stem cells
Normal mammary stem cells (MaSCs) possess properties 
such as multipotency and self-renewal. Th  is is demon-
strated in vivo by the formation of a functional mouse 
mammary gland from a single MaSC [75], whereas 
mammo  sphere assays are used to determine properties of 
MaSCs  in vitro. Sub-populations of primary human 
mammary epithelial cells (HMECs) grown as single cells 
in mammosphere culture can produce both diﬀ  erentiated 
luminal and myoepithelial cells, while the remaining un-
diﬀ  erentiated progeny are able to recapitulate the same 
multipotent phenotype in successive mammosphere 
passages [76]. If a tumor cell were endowed with these 
attributes, it would possess assets beneﬁ   cial for the 
establish  ment of a secondary site. For example, coloniz-
ing a distant site involves the expansion of cancer cells 
that, at least initially, would be expected to contain a 
stem/progenitor-like cell to spawn the new tumor. Not 
surprisingly then, cells isolated from breast cancers can 
also form mammospheres, or tumorspheres. Th  ese  cells 
have an enriched CD44+/CD24- cell surface proﬁ  le [77], 
which marks the same population of cells that have 
increased tumor-initiation capability in vivo [78]. Th  us,  a 
subset of breast cancer cells possess self-renewing and 
multipotent characteristics similar to MaSCs, as well as 
demonstrate a heightened ability to initiate tumors, and 
are denoted as cancer stem cells (CSCs). It should be said, 
however, that the CSC naming convention does not 
imply totipotency, such as is observed with true stem 
cells. Accordingly, the terms tumor-initiating cell and 
cancer stem-like cell are used interchangeably with CSC 
in the ﬁ  eld.
Because both EMT and CSC phenotypes are implicated 
in metastasis, a connection between EMT and CSCs was 
proposed and recently demonstrated. Indeed, two 
independent groups showed that the CD44high/CD24low 
population of normal and transformed HMECs displayed 
EMT-associated phenotypes when compared to CD44low/
CD24high cells [4,5]. Importantly, the reverse experiment 
of inducing an oncogenic EMT with TWIST1, SNAI1 or 
TGFB1 led to an increase in CD44high/CD24low cells and 
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Page 6 of 13Figure 2. Epithelial-to-mesenchymal transition may contribute to metastasis through multiple mechanisms. (a) Carcinoma cells that 
undergo an oncogenic epithelial-to-mesenchymal transition (EMT) may cooperate with epithelial tumor cells to stimulate metastasis. In this 
example, mesenchymal-like tumor cells, arising from an exogenously induced oncogenic EMT, are required to enable the parental epithelial tumor 
cell access to the vasculature; however, once both cell types have accessed the vasculature, only the epithelial cell is able to colonize the secondary 
site. In this model, the tumor cells are not plastic, and exist as two distinct populations. (b) Tumor cells that are plastic can carry out both early 
and late stages of the metastatic cascade by utilizing the mesenchymal-like state to leave the primary tumor and enter the vasculature, while the 
epithelial state is needed to colonize a secondary site; a combination of strictly epithelial and mesenchymal-like cancer cells is not needed.
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Page 7 of 13tumor-initiation frequency [4,5], demonstrating a causal 
role for EMT inducers in CSC formation. SIX1 [20,79], 
SNAI2 [80], TWIST2 [18], FOXQ1 [39], TNF [16] and 
TP53 [40] have all since been shown to induce an EMT 
and also increase breast CSC features, further establish-
ing an EMT-CSC relationship. Analysis of breast cancer 
tissue additionally strengthened the EMT-CSC associa-
tion by identifying a signiﬁ  cant correlation between the 
claudin-low subtype of breast cancers with gene expres-
sion signatures for both EMT and CSCs [81]. Interest-
ingly, the miR-200 family is down-regulated in these 
tumors [82], and these miR family members have been 
shown to target BMI1 polycomb ring ﬁ  nger oncogene 
(BMI1) [83] and Suppressor of zeste 12 homolog (SUZ12) 
[84], polycomb repressive complex members with positive 
roles in self-renewal [84,85]. BMI1 is more highly 
expressed in breast cancer metastases when compared to 
matched primary tumors [86], again connecting EMT 
and CSC phenotypes with metastasis.
EMT, cancer stem cells and therapeutic resistance
Conventional breast cancer treatment includes chemo-
therapy and radiotherapy, and while these treatment 
options are commonly used, many patients will ultimately 
relapse due to the presence of residual cancer cells that 
are presumably treatment-resistant. Recent research has 
begun to look at EMT and CSCs as one mechanism by 
which tumors are treatment-resistant. An in vitro study 
using radiation therapy reported increased resistance in 
cells grown as mammospheres, which contain a relatively 
high CSC population, versus monolayer cultures [6]. Th  is 
result was extended by irradiating mice with mammary 
tumors and examining CSC abundance, noting an increased 
percentage of CSCs in residual cells from irradiated mice 
compared to untreated mice [87]. Regarding chemo resis-
tance, examination of breast tumors after neo-adjuvant 
chemotherapy revealed an increase in the CSC-enriched 
CD44high/CD24-/low population [88]. Additionally, a 
‘mammosphere-CD44+/CD24-/low’ gene expression signa-
ture constructed from breast tumors applied to biopsies 
pre- and post-endocrine therapy or chemotherapy 
demon  strated an increased correlation of the mammo-
sphere-CD44+/CD24-/low gene expression signature with 
the post-treatment samples [7]. Importantly, samples 
obtained after treatment were also enriched in EMT-
related mesenchymal markers [7], again highlighting a 
relationship between oncogenic EMT and CSCs. Indeed, 
oncogenic EMTs have themselves been linked to thera-
peutic resistance, as highlighted in a recent study by Li 
and colleagues [89]: doxorubicin treatment increased the 
fraction of EMT-like cells in vitro, and the cells that 
underwent an oncogenic EMT were resistant to 
vincristine and pacilitaxel. It remains unclear whether 
conventional therapy induces an EMT or CSC phenotype 
or whether therapies select for cells that have undergone 
an oncogenic EMT and/or CSC-like conversion. Which-
ever the case, these studies provide strong justiﬁ  cation 
for increased research to understand the role of 
oncogenic EMT and CSCs in therapy resistance, so that 
knowledge gained can be applied towards improving 
breast cancer treatment.
Therapeutic implications
Studies on the role of EMT and CSCs in metastasis and 
therapeutic resistance may signiﬁ   cantly impact how 
breast cancer patients are treated in the future. If 
mediators of oncogenic EMT and/or CSC phenotypes 
are known, blocking the eﬀ  ects of such mediators should 
sensitize tumor cells to treatment. In fact, recent studies 
demonstrate that such approaches may ultimately have 
eﬃ     cacy in the clinic. Inhibition of TWIST1 during 
doxorubicin-induced/enriched oncogenic EMT signiﬁ  -
cantly increased survival and decreased pulmonary and 
lymph node metastases in a mouse xenograft model in 
vivo [89]. Since TWIST1 increases were mediated in part 
by mitogen-activated protein kinase signaling, it was 
demonstrated that treatment of cells in vitro with a MEK 
inhibitor could prevent TWIST1 up-regulation [62]. 
Th  ese data suggest that combination treatment with 
MEK inhibitors and doxorubicin may be a potent 
mechanism to decrease metastasis, but this ﬁ  nding must 
ﬁ  rst be tested in vivo.
In another study, performed by Joseph and colleagues 
[90], breast cancer cell lines were treated with the 
telomerase inhibitor Imetelstat. Th  e authors demon-
strated an overall decrease in the CD44+/CD24- cell 
population and in mammosphere propagation in vitro, 
while in vivo Imetelstat treatment led to a 50% decrease 
in tumor initiation. It will thus be of interest to combine 
Imetelstat with conventional therapy in the future, to 
determine the combined eﬀ   ects of the drugs on 
metastasis.
Additional studies have demonstrated that combination 
therapy can inﬂ   uence both the CSC population and 
metastasis. For example, mice treated with docetaxel in 
combination with repertaxin, a CXCR1/2 small-molecule 
inhibitor, exhibited a reduction in the CD44+/CD24- 
population in their primary mammary tumors and a 
decrease in systemic metastases [91]. Since the Imetelstat 
and repartaxin studies did not directly address the role of 
oncogenic EMT in the observed eﬀ  ects on CSCs, it would 
be of interest to investigate this relationship. Overall 
though, the established EMT-CSC link has led 
researchers down a worthwhile path towards discovering 
novel therapeutic targets.
Studies by Gupta and colleagues [92] have recently laid 
the groundwork for further innovative, anti-oncogenic 
EMT/CSC approaches to developing new therapies. By 
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Page 8 of 13employing an induced EMT model to enrich for CD44high/
CD24low cells, a high-throughput screen was used to 
identify drugs that target the breast CSC population, 
resulting in the discovery of salinomycin as a drug that 
preferentially kills mesenchymal-like CSCs. Salinomycin 
treatment was found to decrease the CD44high/CD24low 
Figure 3. Clinical implications of the plasticity of cancer stem cells. (a) The initial tumor is composed of non-cancer stem cells (CSCs; yellow) 
and the rare CSCs (red). Non-CSCs within the tumor can mutate, resulting in a genetically distinct non-CSC (blue). Spontaneous conversion of this 
new non-CSC (blue) into a new CSC (green) provides a given tumor with genetically distinct CSCs (red and green) that can foster the outgrowth 
of diff  erent clonal populations. (b) Conventional therapy is known to be ineff  ective at eliminating CSCs, which allow tumor cells to eventually 
repopulate (left); however, targeting solely CSCs will leave the bulk of the tumor intact (middle). A remaining tumor cell could then convert into a 
CSC, allowing for tumor recurrence and metastasis. Combination therapies targeting both CSCs and non-CSCs are likely needed to better prevent 
tumor recurrence and metastasis (right).
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Page 9 of 13cell population and to lower mammosphere-forming 
eﬃ   ciency in vitro, as well as lead to a reduction in tumor-
initiating frequency and lung metastases when compared 
to paclitaxel treatment in vivo [92]. Interestingly, primary 
tumor and metastatic cells surviving salinomycin 
treatment did not display the EMT phenotype observed 
in cells that survived paclitaxel treatment [92]. Th  us, 
combined paclitaxel and salinomycin might be expected 
to kill both the bulk tumor as well as the CSCs within the 
tumor. Additional studies investigating therapies that 
reduce EMT/CSC populations can be found in alternative 
reviews [93-95].
While many new therapeutic eﬀ  orts are focusing on 
targeting EMT-like cells/CSCs, one must remain mindful 
of tumor cell heterogeneity when developing such 
therapies. Geyer and colleagues [96] demonstrated that 
microdissected metaplastic primary breast tumors and 
matched metastatic samples contain intratumoral genomic 
diﬀ  erences, in addition to similarities. Th   is indicates that 
either a single cancer cell did not give rise to the entire 
tumor, or that distinct genetic alterations occurred in the 
progeny of the tumor-initiating cell, giving rise to 
multiple intratumoral clonal populations. Th   e clonal pro-
pa  gation of cells with newly arising mutations may 
explain intratumoral genotypic hetero  geneity, such as 
metastases that contain both ampliﬁ   ed and non-
ampliﬁ  ed  HER2 intratumoral populations [96], but it 
does not necessarily explain phenotypic, or state of 
diﬀ  erentiation, heterogeneity within tumors of the same 
genotype.
Shedding light on intratumoral genotypic and pheno-
typic heterogeneity are recent studies from the Weinberg 
and Struhl laboratories. Both groups presented evidence 
for the conversion of normal and neoplastic non-stem 
cell populations into functional stem cell populations in 
vitro  and  in vivo, using hTert (TERT) immortalized 
HMECs and vSrc (SRC) transformed MCF10A human 
mammary cells [97,98]. Building upon the data, a model 
addressing genotypic and phenotypic heterogeneity 
arises where the non-CSC progeny of a metastasized 
CSC could potentially convert back to a CSC, complete 
with any gained genomic diﬀ  erences  (genomic 
heterogeneity). Th   is genetically distinct CSC could then 
spawn a new clonal population of more and less diﬀ  er-
entiated cells (phenotypic heterogeneity), either within 
the same tumor or at a new site (Figure 3a). In support of 
such a model, next generation sequencing of 100 
individual nuclei from a polygenomic, triple negative 
human breast tumor indicated punctuated clonal evolu-
tion [99]. Rather than observing a gradual progression of 
genetic changes in tumor cell populations, no 
intermediate genotypes were found between the diﬀ  erent 
populations, and in fact the authors noted the ‘rate of 
eﬀ  ective population growth markedly exceeds [the] rate 
of genomic evolution’ [99]. Multiple mutations in a 
cancer cell that converts to a progenitor-like cell (that is, 
CSC) could explain such diﬀ  erences. Most importantly 
though, if genetically distinct CSC and non-CSC 
populations exist within an individual, multiple therapies 
may ultimately be required for increased prognosis.
Th  e take home message from these studies is that 
targeting the oncogenic EMT/CSC-like population alone 
is unlikely to be suﬃ   cient to inhibit tumor progression 
and metastasis. Th  e central theme of future research, 
then, should be that both the CSC and the bulk tumor 
population must be eﬀ  ectively targeted to attain the best 
patient response (Figure 3b). It has been suggested that 
the ability of non-CSC populations to convert to CSCs 
may help attain this goal [97]. Obtaining non-CSCs from 
an individual patient should spontaneously yield, as 
observed with cell lines [97,98], naturally arising 
personalized CSCs to be used for predictive testing of an 
individual’s response to a particular therapy. Along those 
lines, mouse claudin-low tumors were recently shown to 
functionally contain more CSCs than other breast cancer 
subtypes, yielding a new model to both identify CSC 
targets and test resulting therapies [82].
Conclusions
While epithelial cancers may metastasize via various 
mechanisms, including, but not restricted to, their ability 
to induce oncogenic EMT, it is clear that epithelial 
plasticity is an important means by which carcinoma 
cells can acquire numerous pro-metastatic charac  ter-
istics. Deﬁ   ning an oncogenic EMT by precise mesen-
chymal and epithelial alterations runs counter to the fact 
that these cells are plastic and not created equal: each 
possesses a diﬀ  erent metastatic potential that is either 
harnessed or repressed by the host. In closing, it is 
indisputable that studies related to oncogenic EMT have 
critically contributed to, and will continue to contribute 
to, our understanding of the most devastating aspect of 
breast cancer: metastatic dissemination.
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